Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trial

Background: Hetrombopag has been approved for chronic ITP (duration >12 months). However, its efficacy and safety in persistent ITP (duration 3–12 months) remain unexplored. Objectives: This post-hoc analysis aimed to evaluate the efficacy and safety of hetrombopag in persistent ITP patients and com...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Heng Mei, Xiaofan Liu, Yan Li, Hu Zhou, Ying Feng, Guangxun Gao, Peng Cheng, Ruibin Huang, Linhua Yang, Jianda Hu, Ming Hou, Yazhou Yao, Li Liu, Yi Wang, Depei Wu, Xuliang Shen, Jie Jin, Jianmin Luo, Yun Zeng, Xin Zhou, Ruixiang Xia, Zhongxing Jiang, Yuansong Bai, Liping Wang, Ting Niu, Renchi Yang, Yu Hu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-10-01
Edice:	Research and Practice in Thrombosis and Haemostasis
Témata:	hetrombopag persistent immune thrombocytopenia platelet response thrombopoietin receptor agonist
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2475037925005291
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!